Chinese biosimilar developer Bio-Thera Solutions Ltd. has announced positive results from its Phase III study into its asset BAT2206, a proposed biosimilar to Stelara (ustekinumab). The results demonstrated that BAT2206 is highly similar to Stelara in patients with moderate to severe plaque psoriasis.
The global, multi-center, randomized, double-blind, parallel-arm Phase III study compared the efficacy, safety, immunogenicity and pharmacokinetics of BAT2206 and Stelara...






